Synthesis of 1,2,3‐Triazole and Isoxazole Derivatives of [1,2,4]Triazolo[3,4‐b][1,3,4]thiadiazine as Potent EGFR Targeting Antilung Cancer Agents
Chemistry & Biodiversity · 2026
DOI: 10.1002/cbdv.202502795 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemistry & Biodiversity, 2026. Verfasst von Arvapalli Kiran Kumar und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, Chaitanya (Deemed to Be University), Hyderabad, India. Hauptthemen laut MEDLINE: Triazoles, Antineoplastic Agents, Isoxazoles, Protein Kinase Inhibitors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 64 Literaturangaben.
Abstract (Originalsprache)
Imidazole‐1,2,4triazolo[3,4‐b][1,3,4]thiadiazines associated 1,2,3‐triazole and isoxazole hybrids were designed and synthesized using a pharmacophore‐hybridization approach that incorporates physiologically active scaffolds. In vitro anticancer activity of the synthesized compounds was screened against two lung cancer cell lines, A‐549 and NCI‐H460, and results revealed that compounds 6d and 6h had substantial efficacy compared to the standard erlotinib. Furthermore, compound 6h (IC 50 = 0.61 ± 0.12 µM) exhibited greater effectiveness as compared to the conventional Erlotinib (IC 50 = 0.64 ± 0.23 µM) in vitro, as shown by EGFR inhibitory tests, whereas compound 6d (IC 50 = 0.65 ± 0.09 µM) indicated notable EGFR inhibitory action. To confirm the activity findings, five potent compounds underwent in silico molecular docking studies, with all compounds demonstrating superior binding energies relative to the standard.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemistry, Chaitanya (Deemed to Be University), Hyderabad, India.
- Department of Physical Sciences/Chemistry, Kakatiya Institute of Technology & Science (Autonomous), Warangal, India.
- Department of Biotechnology, Chaitanya (Deemed to Be University), Hyderabad, India.
ORCID-Profile: Sirassu Narsimha
Zitieren
APA
Kumar, A. K., Reddy, T. M., Kavela, S., Narsimha, S., & Siddoju, K. (2026). Synthesis of 1,2,3‐Triazole and Isoxazole Derivatives of [1,2,4]Triazolo[3,4‐b][1,3,4]thiadiazine as Potent EGFR Targeting Antilung Cancer Agents. Chemistry & Biodiversity. https://doi.org/10.1002/cbdv.202502795
Vancouver
Kumar AK, Reddy TM, Kavela S, Narsimha S, Siddoju K. Synthesis of 1,2,3‐Triazole and Isoxazole Derivatives of [1,2,4]Triazolo[3,4‐b][1,3,4]thiadiazine as Potent EGFR Targeting Antilung Cancer Agents. Chemistry & Biodiversity. 2026. doi:10.1002/cbdv.202502795
BibTeX
@article{Kumar2026,
author = {Kumar, Arvapalli Kiran and Reddy, T Madhukar and Kavela, Sridhar and Narsimha, Sirassu and Siddoju, Kavitha},
title = {Synthesis of 1,2,3‐Triazole and Isoxazole Derivatives of [1,2,4]Triazolo[3,4‐b][1,3,4]thiadiazine as Potent EGFR Targeting Antilung Cancer Agents},
journal = {Chemistry & Biodiversity},
year = {2026},
doi = {10.1002/cbdv.202502795}
}
EUVIMED